Fee Structure and Budgeting for Medical Device Registration in Myanmar

1. Key takeaways

For Myanmar medical device registration, fees cannot be given as a single fixed figure. The figures quoted by public sources conflict with one another, ranging from approximately MMK 500,000 to 3,000,000, to USD 3,000 to 6,000, to USD 800 per model — differences of several times over. GRZAN’s handling principle is: mark all fees as a practical estimate, and defer to the official payment notice issued by the Myanmar FDA. Until that notice is issued, every number in circulation is an estimate of unknown quality rather than a quote.

GRZAN insight: the roots of the fee divergence are three. First, different risk classifications lead to different depths of review; second, different service scopes (whether local agency, translation, notarisation, and testing are included); third, exchange rate and currency-of-quotation differences (MMK versus USD). When building their cost models, companies should first define the boundary of the services they are buying, and then confirm the current fee rates with the competent authority. Only then do the numbers being compared describe the same thing.

• Conflicting ranges — approximately MMK 500,000 to 3,000,000 (tiered by category); USD 3,000 to 6,000 (all classes A/B/C/D); USD 800 per model (single source).
• Governing principle — treat every published figure as a practical estimate and rely on the official payment notice issued by the Myanmar FDA.
• Three sources of divergence — risk classification, service scope, and exchange rate or currency differences.

2. Legal basis

The table below sets out the fee landscape and the rules for handling it. It records the conflicting ranges reported by public sources, the governing principle of deferring to the official payment notice, the three sources of divergence, and the related institutional and procedural items that surround the payment process.

3. Expert insights

Insight 1: the conflicting figures are themselves information, and should not be smoothed over by taking a median. The statistical bases, service scopes, and reference dates of the different sources all differ, so averaging them manufactures false precision. A median drawn from numbers that describe different things tells the budget planner nothing useful; the correct response is to understand why each source differs, not to collapse the differences into a single misleading point estimate.

Insight 2: classification is the first variable of cost. The depth of review for Class A and Class D devices differs significantly, so fees necessarily fall into tiers. A low-risk device travels through a lighter review and a high-risk device through a heavier one, and the fee schedule reflects that difference. Companies budgeting several products should therefore build the budget by class rather than assuming one figure covers the portfolio.

Insight 3: service scope is the underestimated second variable. For the same product, whether local agency and testing are included can make total expenditure differ several times over. Two quotes that differ dramatically may both be correct within their own boundaries — one includes local agency, translation, notarisation, and testing, while the other covers only the regulatory fee. Comparing them without aligning scope first produces a decision that looks informed and is not.

Insight 4: exchange rate volatility makes MMK-denominated fees difficult to convert. Companies should require that the currency and amount stated on the payment notice govern. A dollar conversion made today can be wrong next month, and the payment obligation itself is defined in the currency the authority writes on the notice, so planning around a converted figure introduces a risk that belongs to no one and is managed by no one.

Insight 5: the budget should separate government fees from professional service fees. The two are determined and paid in entirely different ways and must not be mixed in one line. Government fees follow the authority’s official payment notice; professional service fees follow negotiated contracts whose scope varies by provider. Keeping the two separate preserves the ability to verify each against its own source and to spot where a divergence actually arises.

4. Practical recommendations

• Separate government fees from professional service fees in the budget table. List and estimate the two categories separately.
• Use the currency and amount stated on the official payment notice as the governing figures. Do not rely on second-hand converted numbers.
• Estimate costs in tiers according to risk classification. Do not share a single budget basis across low-risk and high-risk products.
• Reserve a buffer for exchange rate fluctuations. This applies especially to the portion denominated in MMK.
• Define the service scope before comparing prices. Only after the scope is unified can offers be compared on a like-for-like basis.

5. Verification checklist

• □ Separated government fees from professional service fees
• □ Obtained the official payment notice from the competent authority
• □ Estimated costs in tiers according to risk classification
• □ Reserved a buffer for exchange rate fluctuations
• □ Unified the service scope basis before comparing prices
• □ Recorded the date on which the fee figures were queried
• □ Incorporated the registration ledger into management

Regulatory information verified as of 29 October 2026.

In the Southeast Asian market, GRZAN’s core strengths concentrate on three points. First, distinguishing the legislative progress of each ASEAN member state’s dedicated medical device law — Singapore, Malaysia, Thailand, Indonesia, the Philippines, Vietnam and others have each established their own written medical device regulatory framework, whereas Myanmar has not yet enacted a dedicated law; its rules are assembled from three layers: the technical framework of the ASEAN Medical Device Directive, administrative guidance from the competent authority, and the catch-all authorisation of the Public Health Law 1972, so compliance certainty is markedly lower than in markets where dedicated legislation is complete. Second, local authorised representative services, in which GRZAN can act as the statutory representative of the manufacturer in these countries, carrying registration submissions, regulatory communications, and post-market reporting obligations. Third, quality system and laboratory testing support, assisting in establishing a quality management system that meets ISO 13485 requirements and connecting with locally accredited laboratory resources.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Myanmar. Our team prepares the technical dossier to ASEAN CSDT structure, manages submission and deficiency responses with the Myanmar FDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com